Special Issue "Integrins in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 May 2017).
Interests: molecularly targeted therapeutics; design and synthesis of novel integrin antagonists; multitargeted drugs; combination therapies; peptidomimetics; natural products
The integrin family of cell adhesion receptors have been shown to play fundamental roles in cell growth, differentiation, motility, and survival. Changes in the expression and activation of integrins are commonly observed in cancers and promote tumour growth, neoangiogenesis, and metastatic dissemination. More recently, the involvement of integrins has been established in site specific metastasis, cancer stem cells, drug resistance via signalling pathways such as β3-KRAS-RalB-NF-κB, β1-Src-Akt and the osteopontin signalling axis, and contributing to tumour immune evasion through activation of TGF-β.
Antibody and small molecule integrin antagonists have been successfully developed for use in acute coronary syndromes (targeting αIIbβ3), multiple sclerosis and inflammatory bowel disease (targeting α4β1/α4β7), however the development of integrin-targeted anticancer agents has proved more challenging. Drugs such as Cilengitide (targeting αvβ3/αvβ5) showed promising preclinical results but did not deliver survival benefits in the clinic.
Developing understanding of the complexity of integrin function, structural requirements for pure antagonism or agonism, and the contribution of multiple integrin receptors and receptor tyrosine kinases to intracellular signalling pathways will support the development of the next generation of integrin targeted agents and multi-targeting strategies to effectively control tumour progression. Research on less investigated integrins, including αvβ6, αvβ8, and α8β1, should yield new diagnostic and therapeutic modalities in emerging areas such as immuno-oncology, and areas of unmet clinical need. This Special Issue will highlight the current state of the art in integrin biology, integrin targeting, and future prospects for improving therapies.
Dr. Helen M Sheldrake
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Tumour-microenvironment interaction
- cell adhesion mediated drug resistance
- targeted therapy